Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 0.50 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8318328 | 1.00 | PLD1 (0.50) | PLD1CHI3L1GRM1GRIN2BGRIN2D | |
| SCHEMBL29505439 | 0.90 | GRM1 (0.49) | PLD1GRM1KDM4E | |
| SCHEMBL1245662 | 0.89 | PLD1 (0.58) | PLD1CHI3L1GPR119KDM4E | |
| Trifluoroacetic Acid SCHEMBL4749328 | 0.87 | DPP4 (0.60) | GRM1GPR119KDM4E | |
| SCHEMBL2294733 | 0.85 | GRIN2B (0.55) | PLD1GRM1GRIN2BGRIN2DGRIN3B | |
| SCHEMBL30937159 | 0.85 | GRIN2B (0.55) | PLD1GRM1GRIN2BGRIN2DGRIN3B | |
| SCHEMBL30146719 | 0.85 | PDE10A (0.41) | CHI3L1GRM1PDE10A | |
| SCHEMBL16474292 | 0.81 | PLD1 (0.51) | PLD1GRM1GRIN2BGRIN2DGRIN3B | |
| SCHEMBL23875675 | 0.79 | GRM1 (0.51) | PLD1GRM1GRIN2BGRIN2DGRIN3B | |
| SCHEMBL8091809 | 0.79 | GRM1 (0.51) | PLD1GRM1GRIN2BGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023019912-A9 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023019912-A1 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-02-23 | — | — | WO | disclosed |
| CN-111333625-B | Phenyl pyrrolidine compounds and uses thereof | 武汉人福创新药物研发中心有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-111333625-A | Phenyl pyrrolidine compounds and uses thereof | 湖北生物医药产业技术研究院有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-20050267156-A1 | Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. | 2005-12-01 | — | — | US | disclosed |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-0974602-B1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR CORP (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-0757051-B1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6291596-B1 | CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT | JSR CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0974602-A1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
| EP-0774465-A1 | Penem derivatives and antimicrobial agents containing the same | SUNTORY LIMITED (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0757051-A1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | MRPL21, MRPS2, MRPS28 | PLD1 3466/4885CHI3L1 2722/4885GRM1 475/4885 |
| US-20050267156-A1 | Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors | PRSS1, SPINT2, TMPRSS2 | PLD1 2313/4885CHI3L1 2634/4885GRM1 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.